Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy

ABSTRACT Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in critically ill patients. Considerable pharmacokinetic (PK) variability is observed in critically ill patients. By estimating an individual's PK, dosage optimization Bayesian estimation techniques can be used to calculate the appropriate piperacillin regimen to achieve desired drug exposure targets. The aim of this study was to establish a population PK model for piperacillin in critically ill patients and then analyze the performance of the model in the dose optimization software program BestDose. Linear, with estimated creatinine clearance and weight as covariates, Michaelis-Menten (MM) and parallel linear/MM structural models were fitted to the data from 146 critically ill patients with nosocomial infection. Piperacillin concentrations measured in the first dosing interval, from each of 8 additional individuals, combined with the population model were embedded into the dose optimization software. The impact of the number of observations was assessed. Precision was assessed by (i) the predicted piperacillin dosage and by (ii) linear regression of the observed-versus-predicted piperacillin concentrations from the second 24 h of treatment. We found that a linear clearance model with creatinine clearance and weight as covariates for drug clearance and volume of distribution, respectively, best described the observed data. When there were at least two observed piperacillin concentrations, the dose optimization software predicted a mean piperacillin dosage of 4.02 g in the 8 patients administered piperacillin doses of 4.00 g. Linear regression of the observed-versus-predicted piperacillin concentrations for 8 individuals after 24 h of piperacillin dosing demonstrated an r2 of >0.89. In conclusion, for most critically ill patients, individualized piperacillin regimens delivering a target serum piperacillin concentration is achievable. Further validation of the dosage optimization software in a clinical trial is required.

[1]  M. Neely,et al.  Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa , 2013, Antimicrobial Agents and Chemotherapy.

[2]  R. Jelliffe,et al.  Software for Dosage Individualization of Voriconazole for Immunocompromised Patients , 2013, Antimicrobial Agents and Chemotherapy.

[3]  R. Bellomo,et al.  Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Verstraete,et al.  Quantification of seven β-lactam antibiotics and two β-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. , 2012, International journal of antimicrobial agents.

[5]  J. Roberts,et al.  A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  P. Viale,et al.  Dosing Nomograms for Attaining Optimum Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach , 2012, Antimicrobial Agents and Chemotherapy.

[7]  Alan Schumitzky,et al.  Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R , 2012, Therapeutic drug monitoring.

[8]  G. Drusano,et al.  Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections , 2012, Antimicrobial Agents and Chemotherapy.

[9]  D. Paterson,et al.  Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patients—A One-Year Prospective Study , 2012, Therapeutic drug monitoring.

[10]  C. Aubron,et al.  Vancomycin Dosing: Assessment of Time to Therapeutic Concentration and Predictive Accuracy of Pharmacokinetic Modeling Software , 2011, The Annals of pharmacotherapy.

[11]  N. Rakhmanina,et al.  Pharmacokinetic Optimization of Antiretroviral Therapy in Children and Adolescents , 2011, Clinical pharmacokinetics.

[12]  D. Paterson,et al.  Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. , 2010, International journal of antimicrobial agents.

[13]  J. Rello,et al.  Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia , 2010, European Respiratory Journal.

[14]  D. Paterson,et al.  Pharmacokinetic evaluation of piperacillin-tazobactam , 2010, Expert opinion on drug metabolism & toxicology.

[15]  J. Roberts,et al.  Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? , 2010, International journal of antimicrobial agents.

[16]  M. Roberts,et al.  First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. , 2010, International journal of antimicrobial agents.

[17]  G. Drusano,et al.  Identification of Optimal Renal Dosage Adjustments for Traditional and Extended-Infusion Piperacillin-Tazobactam Dosing Regimens in Hospitalized Patients , 2009, Antimicrobial Agents and Chemotherapy.

[18]  M. Moss,et al.  The epidemiology of sepsis. , 2008, Current pharmaceutical design.

[19]  T. Rimmele,et al.  Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia* , 2008, Critical care medicine.

[20]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  G. Drusano,et al.  Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[23]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[24]  Vincent H. Tam,et al.  Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.

[25]  G. Drusano,et al.  Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation , 2004, Antimicrobial Agents and Chemotherapy.

[26]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[27]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[28]  H. Bruining,et al.  Experience with a once-daily dosing program of aminoglycosides in critically ill patients , 2002, Intensive Care Medicine.

[29]  A. Vinks,et al.  Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. , 1999, Therapeutic drug monitoring.

[30]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[31]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[32]  G. Richards,et al.  The epidemiology of sepsis. , 1973, Clinical orthopaedics and related research.

[33]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[34]  Jason A Roberts,et al.  Therapeutic drug monitoring of antimicrobials. , 2012, British journal of clinical pharmacology.

[35]  J. Roberts,et al.  Antibacterial Dosing in Intensive Care Pharmacokinetics, Degree of Disease and Pharmacodynamics of Sepsis , 2012 .

[36]  J. Ahlner,et al.  THERAPEUTIC DRUG MONITORING AND CLINICAL TOXICOLOGY , 2009 .

[37]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[38]  R W Jelliffe,et al.  Pharmaco-informatics: more precise drug therapy from 'multiple model' (MM) adaptive control regimens: evaluation with simulated vancomycin therapy. , 1995, Medinfo. MEDINFO.